Oncogenes and Tumor Suppressors

Cancer is fundamentally a disease of gene regulation. Understanding oncogenes and tumor suppressors—the yin and yang of cancer biology—is essential for understanding how normal cells become cancerous.

Skeptic's corner: Not all mutations are created equal. Driver mutations cause cancer; passenger mutations are just along for the ride. The challenge is distinguishing between them and understanding their context.

---

The Two-Hit Hypothesis

Knudson's Model (1971)

• Tumor suppressors: Require both alleles to be inactivated
• Oncogenes: Require only one allele to be activated
• Implications: Different mutation patterns and inheritance

Modern Understanding

• Multiple hits: Cancer requires 4-6 driver mutations
• Temporal order: Some mutations must occur before others
• Context matters: Same mutation can have different effects

---

Oncogenes: The Accelerators

Oncogenes are mutated versions of normal genes (proto-oncogenes) that promote cancer when activated.

Mechanisms of Activation

Point Mutations

• Example: RAS family (KRAS, NRAS, HRAS)
• Effect: Constitutive activation
• Frequency: ~30% of all cancers

Gene Amplification

• Example: MYC, HER2, CCND1
• Effect: Overexpression
• Frequency: ~15% of all cancers

Chromosomal Translocations

• Example: BCR-ABL, MYC-IGH
• Effect: Fusion proteins or overexpression
• Frequency: ~10% of all cancers

Epigenetic Changes

• Example: Promoter hypomethylation
• Effect: Overexpression
• Frequency: Variable

---

Tumor Suppressors: The Brakes

Tumor suppressors are genes that normally prevent cancer by controlling cell growth, DNA repair, and apoptosis.

Mechanisms of Inactivation

Point Mutations

• Example: p53, RB, APC
• Effect: Loss of function
• Frequency: ~50% of all cancers

Deletions

• Example: CDKN2A, PTEN
• Effect: Complete loss
• Frequency: ~20% of all cancers

Epigenetic Silencing

• Example: Promoter hypermethylation
• Effect: Transcriptional silencing
• Frequency: ~15% of all cancers

---

Key Oncogenes

RAS Family

• Genes: KRAS, NRAS, HRAS
• Function: GTPase signaling
• Mutations: G12V, G13D, Q61H
• Cancers: Pancreatic, colorectal, lung
• Therapeutic status: Difficult to target

MYC

• Function: Transcription factor
• Activation: Amplification, translocation
• Cancers: Burkitt lymphoma, neuroblastoma
• Therapeutic status: Experimental

HER2 (ERBB2)

• Function: Receptor tyrosine kinase
• Activation: Amplification, overexpression
• Cancers: Breast, gastric
• Therapeutic status: Targeted (Trastuzumab)

PIK3CA

• Function: PI3K catalytic subunit
• Mutations: H1047R, E545K
• Cancers: Breast, colorectal, endometrial
• Therapeutic status: Targeted (Alpelisib)

---

Key Tumor Suppressors

p53 (TP53)

• Function: Master regulator, apoptosis
• Mutations: R175H, R248Q, R273H
• Cancers: Most cancer types
• Therapeutic status: Experimental

RB (RB1)

• Function: Cell cycle control
• Mutations: Deletions, point mutations
• Cancers: Retinoblastoma, osteosarcoma
• Therapeutic status: CDK4/6 inhibitors

APC

• Function: Wnt pathway regulation
• Mutations: Truncating mutations
• Cancers: Colorectal, desmoid tumors
• Therapeutic status: Wnt inhibitors

PTEN

• Function: PI3K pathway regulation
• Mutations: Deletions, point mutations
• Cancers: Prostate, endometrial, glioblastoma
• Therapeutic status: PI3K inhibitors

---

Laboratory Techniques

Mutation Detection

# Somatic mutation analysis
import pandas as pd
import numpy as np

def analyze_somatic_mutations(vcf_file, cosmic_db):
    """
    Analyze somatic mutations for oncogenes and tumor suppressors
    """
    # Load VCF file
    mutations = pd.read_csv(vcf_file, sep='\t')
    
    # Load COSMIC database
    cosmic = pd.read_csv(cosmic_db)
    
    # Filter for known cancer genes
    cancer_genes = cosmic['Gene'].unique()
    cancer_mutations = mutations[mutations['Gene'].isin(cancer_genes)]
    
    # Classify mutations
    oncogene_mutations = []
    ts_mutations = []
    
    for _, mutation in cancer_mutations.iterrows():
        gene = mutation['Gene']
        variant = mutation['Variant']
        
        # Check if it's a known oncogene
        if gene in ['KRAS', 'NRAS', 'HRAS', 'MYC', 'HER2']:
            oncogene_mutations.append(mutation)
        
        # Check if it's a known tumor suppressor
        elif gene in ['TP53', 'RB1', 'APC', 'PTEN']:
            ts_mutations.append(mutation)
    
    return {
        'oncogene_mutations': oncogene_mutations,
        'tumor_suppressor_mutations': ts_mutations,
        'total_cancer_mutations': len(cancer_mutations)
    }

Expression Analysis

• qPCR: Gene expression levels
• Western blot: Protein expression
• Immunohistochemistry: Tissue expression
• RNA-seq: Genome-wide expression

---

Clinical Relevance

Diagnostic Markers

• HER2 amplification: Breast cancer treatment
• KRAS mutations: Colorectal cancer treatment
• EGFR mutations: Lung cancer treatment
• BRCA1/2 mutations: Hereditary cancer risk

Therapeutic Targets

Oncogene Targeting

• HER2: Trastuzumab, Pertuzumab
• EGFR: Erlotinib, Gefitinib
• BRAF: Vemurafenib, Dabrafenib
• ALK: Crizotinib, Ceritinib

Tumor Suppressor Restoration

• p53 restoration: Experimental
• RB pathway: CDK4/6 inhibitors
• PTEN restoration: PI3K inhibitors

---

Research Applications

Drug Discovery

1. Target identification: Oncogenes, tumor suppressors
2. Biomarker development: Mutation panels
3. Resistance mechanisms: Secondary mutations

Precision Medicine

1. Molecular profiling: Tumor sequencing
2. Targeted therapy: Mutation-guided treatment
3. Clinical trials: Biomarker-driven studies

---

Practical Considerations

Sample Requirements

• Tumor tissue: Fresh or FFPE
• Normal tissue: Germline comparison
• Blood: Germline DNA

Data Analysis

• Variant calling: GATK, Mutect2
• Annotation: VEP, ANNOVAR
• Pathogenicity: SIFT, PolyPhen, CADD

---

FAQ

Q: Why are oncogenes harder to target than tumor suppressors? A: Oncogenes are often activated by point mutations that are difficult to target, while tumor suppressors can be restored by targeting their pathways.

Q: Can we restore tumor suppressor function? A: This is challenging because it requires replacing the entire gene, but we can target the pathways they control.

Q: How do we know if a mutation is a driver? A: Driver mutations are recurrent, functionally significant, and associated with cancer development.

---

References (APA Style)

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013). Cancer genome landscapes. Science, 339(6127), 1546-1558.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646-674.

Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., ... & Ding, L. (2013). Mutational landscape and significance across 12 major cancer types. Nature, 502(7471), 333-339.

---

Contributing

1. Review existing content for accuracy
2. Add missing oncogenes or tumor suppressors
3. Create practical examples and code snippets
4. Cite recent research and clinical trials

---

This article provides the foundation for understanding how oncogenes and tumor suppressors drive cancer development. Master these concepts to understand cancer biology and targeted therapy.